ENDRA Life Sciences Inc. has announced that it received a letter from The Nasdaq Stock Market LLC on May 27, 2025, indicating non-compliance with the Nasdaq Listing Rule 5550(b)(1). The company's stockholders' equity, reported at $1,752,885 in its recent quarterly report, falls short of the required minimum of $2,500,000 for continued listing on the Nasdaq Capital Market. ENDRA is actively evaluating options to address this deficiency and intends to submit a compliance plan by the July 11, 2025 deadline. The company may be granted until November 23, 2025, to meet the compliance requirements if their plan is accepted. Meanwhile, ENDRA's common stock will continue trading on Nasdaq, but there is no assurance that the compliance plan will be approved or that the company can maintain its listing status.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.